9-2006

Pharmacy Information Link Letter

Aga Khan University Hospital, Nairobi

Follow this and additional works at: https://ecommons.aku.edu/ea_publications

Recommended Citation
Withdrawal of Triapin (Ramipril+Felodipine) from Kenyan market
Sanofi-aventis are no longer importing the above drug due to problems sourcing it for the Kenyan market. Please change your patients to ramipril and felodipine separately or consider other antihypertensive agents.

Glaucoma eye drops
Recently, a consultant ophthalmologist, Dr. Damji visited the hospital from Canada and donated some eye drops to the hospital. These are available free of charge for all patients. Unfortunately they have a short expiry and we urge you to take this opportunity to assist your patients as soon as possible. The drugs available are:
1. Travatan–Trunoprost 0.004% eye drops
2. Alphagan–Brimonidine 0.15% eye drops
3. Lumigan–Bimatoprost 0.03% eye drops

NEW
Sirdalud 2mg and 4mg tablets (tizanidine)

Class
Skeletal Muscle Relaxant, Centrally Acting

Dosage, Adult (usual)
Sparingly, skeletal initial, 4 mg/day ORALLY and gradually increase in 2-4 mg increments on an individual basis over 2-4 weeks; maintenance, 8 mg ORALLY every 8 hr (max dose 36 mg/day)

Dosage, Pediatric, (usual)
safety and efficacy have not been determined in children

Dose Adjustments:
generally use with caution in geriatric patients
renal impairment: use with caution in patients with CrCl less than 25 ml/min (clearance may be reduced by 50%)

Monitoring: reduction in pain and muscle spasms, passive limb movement , blood pressure, hepatic function (aminotransferase); at baseline, at 1, 3, and 6 months of therapy and periodically thereafter, based on clinical status

Contraindications: hypersensitivity to tizanidine products

Precautions:
concomitant use of oral contraceptives (clearance is reduced by approximately 50%)
congestive heart failure or cardiac arrhythmias, hypotension or concurrent antihypertensive medication, liver disease, renal impairment
Drug News cont.

**Adverse Effects**

**COMMON**
- Cardiovascular: Hypotension (Mild) (20%)
- Gastrointestinal: Constipation (3%), Vomiting (3%), Xerostomia (39%)
- Hepatic: Liver function tests abnormal (3%)
- Neurologic: Asthenia (25%), Disturbance in speech (3%), Dizziness (12%), Dyskinesia (3%), Somnolence (26%)
- Ophthalmic: Amblyopia (3%)
- Psychiatric: Nervousness (3%)
- Renal: Urinary tract infectious disease (3%)
- Respiratory: Pharyngitis (2%)

**SERIOUS**
- Cardiovascular: Anginapectoris (rare), Heart failure (rare), Myocardial infarction (rare), Orthostatic hypotension (infrequent), Phlebitis (rare), Syncope (infrequent)
- Dermatologic: Cellulitis (infrequent)
- Gastrointestinal: Gastrointestinal hemorrhage (infrequent)
- Hematologic: Leukopenia (rare), Thrombocytopenia (rare)
- Hepatic: Hepatitis (infrequent)
- Respiratory: Pulmonary embolism (rare)
- Other: Death (infrequent)

**Drug Interactions**
- Amiodarone (major, theoretical), Cimetidine (major, theoretical), Ciprofloxacin (contraindicated, established), Ethinyl Estradiol (major, probable), Fluvoxamine (contraindicated, established), Fosphenytoin (moderate, probable), Lamotrigine (major, probable), Metronidazole (major, probable), Mexiletine (major, theoretical), Norfloxacin (major, theoretical), Phenobarbital (moderate, probable), Propafenone (major, theoretical), Propoxyphene (major, theoretical), Tizanidine (major, theoretical)

**Pregnancy Category: C**

**Breast Feeding:** Infant risk cannot be ruled out

- **NEW**
  - TineaCreme
    - Contains Terbinafine - generic for Lamisil cream

**FDA labeled indications**
- Onychomycosis
- Tinea corporis
- Tinea cruris
- Tinea pedis
<table>
<thead>
<tr>
<th>Reason for Change</th>
<th>Number of Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Change from P/R oral</td>
<td>3</td>
</tr>
<tr>
<td>2. Change to formulary drug from nonformulary drug</td>
<td>17</td>
</tr>
<tr>
<td>3. Doctor not informed could not be reached</td>
<td>9</td>
</tr>
<tr>
<td>4. Dose adjustment in intervention weight based</td>
<td>5</td>
</tr>
<tr>
<td>5. Dose change</td>
<td>92</td>
</tr>
<tr>
<td>6. Drug combusted rated</td>
<td>18</td>
</tr>
<tr>
<td>7. Drug missed on discharge regimen</td>
<td>0</td>
</tr>
<tr>
<td>8. Drug given in pre-mixed pre-packeted feeding</td>
<td>13</td>
</tr>
<tr>
<td>9. Duration/frequency strength not indicated</td>
<td>43</td>
</tr>
<tr>
<td>10. Incorrect frequency</td>
<td>36</td>
</tr>
<tr>
<td>11. Other: dose difficult to measure, drug allergy, wrong drug prescribed</td>
<td>50</td>
</tr>
<tr>
<td>12. Potential interaction between drugs</td>
<td>3</td>
</tr>
<tr>
<td>13. Prescription Negligible</td>
<td>1</td>
</tr>
<tr>
<td>14. Prescription errors</td>
<td>6</td>
</tr>
<tr>
<td>15. Prescription baggage</td>
<td>1</td>
</tr>
<tr>
<td>16. Therapeutic duplication</td>
<td>42</td>
</tr>
<tr>
<td><strong>TOTALS</strong></td>
<td><strong>355</strong></td>
</tr>
</tbody>
</table>

**Bowel cleansing oral sodium phosphates**

**Risk of renal damage**

**USA.** The US FDA has issued an Alert that acute phosphate nephropathy, a type of acute renal failure, is a rare but serious adverse event associated with the use of oral sodium phosphates (OSP) for bowel cleansing. According to the Alert, acute phosphate nephropathy has been documented in 31 patients who used an OSP solution and in one patient who used an OSP tablet. Older individuals, those with kidney disease or decreased intravascular volume, and those using medications that affect renal perfusion or function (diuretics, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and possibly nonsteroidal anti-inflammatory drugs) are at higher risk of acute phosphate nephropathy.


**Glucosamine products**

**86 reports to date in Sweden**

**Sweden.** The Swedish Adverse Drug Reactions Database contains 86 reports of suspected adverse reactions associated with glucosamine products from 2001 until February 2006, according to the Swedish Medical Products Agency. The Agency says that the majority of these cases were reported after 2002. According to the Agency, previously unknown adverse reactions of particular interest included the following: angina pectoris (n = 2), urticaria (1), colitis (2), gastritis/intestinal ulcer (3), edema/lower limb edema (3), dizziness (4), arthritis (2), bronchial asthma/bronchial asthma aggravated (2), diabetes aggravated (2), and hypercholesterolemia (2). There were also three cases of increased effect of Warfarin during concomitant treatment with glucosamine products. (Reports in WHO database: All reactions - 645).

*References:*

Modified Release formulations

These are frequently identifiable by two letters, such as m/r, LA, SA, CR, XL or SR, or the words ‘Retard’ or ‘Slow’ at the end of the name. They are designed to be released gradually over a prolonged period of time, reducing the risk of patients suffering side effects. They are taken just once or twice a day.

Crushing or opening an extended release formulation may damage the mechanism for slow absorption causing the patient to experience dangerous peaks and subtherapeutic troughs in drug-plasma concentration.

The graphs below show how the concentration of drug in the body or plasma varies for both an extended release preparation taken once daily that is swallowed whole and for one that is crushed or opened.

The first graph relates to an extended release preparation that has not been crushed or opened. It does not sharply peak but gradually increases and plateaus before gradually decreasing without reaching the point at which the patient is likely to suffer side effects.

However, if the medicine is crushed or opened before you swallow it, the graph will look like the one below. You can see that there is a very sharp, high peak soon after taking the medicine, and this is when you are extremely likely to suffer what could be severe side effects. The amount of drug in the body then tails off and there will not be enough in the body for it to work properly.

Enteric Coated and Film coated medicines

These usually have the letters EN or EC at the end of the name. They are designed to pass from the stomach into the intestine before releasing the active drug. Crushing or opening the medicine will destroy the enteric coating, which could increase the risk of stomach irritation, releasing the drug in the wrong place or reducing its effectiveness.